leadf
logo-loader
RNS
viewAllergy Therapeutics PLC

Allergy Therapeutics - BLOCK LISTING SIX MONTHLY RETURN

RNS Number : 7735R
Allergy Therapeutics PLC
01 July 2020
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

 

Date: 1 July 2020

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. 

 

 

Name of applicant:

ALLERGY THERAPEUTICS PLC

Name of scheme:

Allergy Therapeutics plc 2013 Long Term Incentive Plan 

Period of return:

From:

11 July 2018  

To:

1 July 2020

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017

Balance of unallotted securities under scheme(s) from previous return:

7,949,152

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-    

Less:  Number of securities issued/allotted under scheme(s) during period:

 1,117,188

 

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

 6,831,964

 

 

Name of contact:

Sara Goldsbrough

Telephone number of contact:

+44 (0) 7966 165719 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

James Stearns, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

[email protected]

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

 

 

 

 

Notes for editors:


About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRKKDBDABKDBOK

Quick facts: Allergy Therapeutics PLC

Price: 12.755

Market: AIM
Market Cap: £81.61 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

3 min read